Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.48 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.48 |
| ▸ | SLC16A8 | O95907 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FABP1 | P07148 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524543 | 0.95 | KMT2A (0.58) | KMT2AMEN1ATMSLC16A3SLC16A7 | |
| SCHEMBL3523363 | 0.86 | SLC16A3 (0.43) | KMT2AMEN1SLC16A3SLC16A7SLC16A8 | |
| SCHEMBL3526360 | 0.84 | PTGES2 (0.48) | SLC16A3SLC16A7SLC16A8HTR5A | |
| SCHEMBL3524588 | 0.84 | CCKBR (0.51) | POLB | |
| SCHEMBL3525579 | 0.81 | CCKBR (0.42) | KMT2AMEN1SLC16A3SLC16A7SLC16A8 | |
| SCHEMBL3519735 | 0.81 | SLC16A3 (0.45) | KMT2AMEN1SLC16A3SLC16A7SLC16A8 | |
| SCHEMBL3528825 | 0.80 | ALDH1A1 (0.56) | KMT2AMEN1SLC16A3ALDH1A1 | |
| SCHEMBL3526026 | 0.78 | PTGES2 (0.50) | — | |
| SCHEMBL3527759 | 0.78 | SLC16A3 (0.48) | KMT2AMEN1SLC16A3SLC40A1ALDH1A1 | |
| SCHEMBL3520453 | 0.77 | ERBB2 (0.47) | KMT2AMEN1ATMALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | KMT2A 2305/4885MEN1 2711/4885ATM 634/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | KMT2A 2990/4885MEN1 4787/4885ATM 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.